Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC) options could extend overall survival (OS) to 16.9 months according to ...

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

Doctors have used chemotherapy (chemo) to treat cancer since the 1940s. The advantage of these drugs is they kill cancer cells throughout your body. One downside is the side effects they can ...

Kate thanked staff at the Royal Marsden Hospital As she thanked staff and comforted patients at the hospital, the royal also opened about her "really tough" chemotherapy and joked about becoming ...

An important question is whether perioperative chemotherapy is preferable to preoperative chemoradiotherapy. In this phase 3, multicenter, randomized trial, we assigned in a 1:1 ratio patients ...

A cancer patient has spent more than 14 years receiving unnecessary chemotherapy, hospital bosses have admitted. Lawyers representing the man claim they know of 12 more patients - all in Coventry ...

“This was achieved with a greater than 70% crossover rate to Libtayo following disease progression on chemotherapy, as well as the largest population of patients with pretreated and clinically ...

A combination of two existing chemotherapy drugs has been used to fight bladder cancer successfully for the first time in Singapore. This new union of the two “off-label” drugs – gemcitabine and ...

The median overall survival with Libtayo (cemiplimab) was 12 months, compared to 8.5 months for the control group, which was treated with chemo selected by investigators. The study enrolled women ...